title: Differences in long-term outcome and prognostic factors according to viral status in patients with hepatocellular carcinoma treated by surgery.
abstract: Long-term postoperative survival and prognostic factors were examined retrospectively in patients with hepatocellular carcinoma (HCC) with serum hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCVAb) and in those without virus infection. Subjects were 265 consecutive HCC patients treated surgically at one institution during the period 1990 to 2006. Postoperative survival was analyzed and compared between HBsAg-positive (B-HCC), HCVAb-positive (C-HCC), and hepatitis B- and C-negative (NBNC-HCC) patients. Prognostic factors for overall and recurrence-free survival were also analyzed. Overall and recurrence-free survival rates were significantly higher in the NBNC-HCC group than in the C-HCC group. Significant prognostic factors for overall survival identified by univariate and multivariate analyses were age, serum alkaline phosphatase (ALP) level, tumor multiplicity, portal vein invasion (Vp), hepatic vein invasion (Vv), and operative blood loss in the B-HCC group; serum albumin level, ALP level, tumor size, and Vv in the C-HCC group; and tumor multiplicity in the NBNC-HCC group. Significant factors for recurrence-free survival were age, ALP level, tumor multiplicity, Vp, and operation time in the B-HCC group; ALP level, prothrombin time, tumor size, Vv, and width of the surgical margin in the C-HCC group; and age, tumor size, tumor multiplicity, and Vp in the NBNC-HCC group. Thus, postoperative survival and prognostic factors in cases of HCC differ according to the presence of serologic viral markers.
authors.affiliation: Department of Surgical Oncology and Regulation of Organ Function, Miyazaki University School of Medicine, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan.
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Kondo
authors.forename: Kazuo
authors.initials: K
authors.lastname: Chijiiwa
authors.forename: Mayumi
authors.initials: M
authors.lastname: Funagayama
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kai
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Otani
authors.forename: Jiro
authors.initials: J
authors.lastname: Ohuchida
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000401:mortality* / Q000601:surgery / Q000821:virology*; D005260:Female; D006503:Hepatic Veins / Q000473:pathology; D006509:Hepatitis B / Q000150:complications; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006526:Hepatitis C / Q000150:complications; D018937:Hepatitis C Antibodies / Q000032:analysis; D006801:Humans; D008111:Liver Function Tests; D008113:Liver Neoplasms / Q000401:mortality* / Q000601:surgery / Q000821:virology*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009361:Neoplasm Invasiveness; D011169:Portal Vein / Q000473:pathology; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D006514:Hepatitis B Surface Antigens; D018937:Hepatitis C Antibodies